OncoImmunology (Dec 2024)

CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent

  • Brendan L.C. Kinney,
  • Brianna Brammer,
  • Vikash Kansal,
  • Connor J. Parrish,
  • Haydn T. Kissick,
  • Yuan Liu,
  • Nabil F. Saba,
  • Zachary S. Buchwald,
  • Mark W. El-Deiry,
  • Mihir R. Patel,
  • Brian J. Boyce,
  • Azeem S. Kaka,
  • Jennifer H. Gross,
  • H. Michael Baddour,
  • Amy Y. Chen,
  • Nicole C. Schmitt

DOI
https://doi.org/10.1080/2162402X.2024.2367777
Journal volume & issue
Vol. 13, no. 1

Abstract

Read online

T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (TEMRA) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.

Keywords